



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
|-----------------|-------------|----------------------|---------------------|------------------|

10/750,164

12/31/2003

J. Nelson Wright

341148020US

5009

69414 7590 11/10/2009  
CALYPSO MEDICAL / PERKINS COIE, LLP  
P.O. BOX 1247  
SEATTLE, WA 98111-1247

EXAMINER

KISH, JAMES M

ART UNIT

PAPER NUMBER

3737

NOTIFICATION DATE

DELIVERY MODE

11/10/2009

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentprocurement@perkinscoie.com  
skempe@perkinscoie.com

1                                   RECORD OF ORAL HEARING  
2                   UNITED STATES PATENT AND TRADEMARK OFFICE

3                                   \_\_\_\_\_  
4                                   BEFORE THE BOARD OF PATENT APPEALS  
5                                   AND INTERFERENCES

6                                   \_\_\_\_\_  
7                                   *Ex parte* J. NELSON WRIGHT and LAURENCE J. NEWELL  
8                                   \_\_\_\_\_

9   Appeal 2009-003286  
10    Application 10/750,164  
11    Technology Center 3700  
12                                   \_\_\_\_\_

13    Oral Hearing Held: October 21, 2009  
14                                   \_\_\_\_\_

15                                   Before TONI R. SCHEINER, RICHARD M. LEBOVITZ, and  
16                                   FRANCISCO C. PRATS, *Administrative Patent Judges*.

17                                   APPEARANCES:

18                                   ON BEHALF OF THE APPELLANTS:

19   SUSAN BETCHER, ESQUIRE  
20   Perkins Coie, L.L.P.  
21   1201 Third Avenue, Suite 4800  
22   Seattle, WA 98101-3099

23                                   The above-entitled matter came on for hearing Monday, October 21,  
24                                   2009, commencing at 9:05 a.m., at the U.S. Patent and Trademark Office,  
25                                   600 Dulany Street, Alexandria, Virginia, before Dominico Quattrociocchi, a  
                                 Notary Public.

P R O C E E D I N G S

1

2

THE USHER: Good morning. Calendar No. 46, Mrs. Betcher.

3

JUDGE SCHEINER: Thank you.

4

THE USHER: You're welcome.

5

JUDGE SCHEINER: Thanks.

6

MS. BETCHER: Morning.

7

JUDGE SCHEINER: Morning. Whenever you're ready you can get

8

started, and you'll have 20 minutes.

9

MS. BETCHER: Okay. Thank you.

10

JUDGE SCHEINER: So unless we ask you a lot of questions and

11

then --

12

MS. BETCHER: Okay.

13

JUDGE SCHEINER: Okay.

14

MS. BETCHER: Good morning.

15

JUDGE SCHEINER: Good morning.

16

MS. BETCHER: Would the Panel permit me to do a brief overview

17

of the technology or would you like me --

18

JUDGE SCHEINER: Certainly. Go ahead.

19

MS. BETCHER: Okay. So Calypso Medical is the -- started in 1999.

20

I've been helping them going through patents for the last nine years. They

21

have approximately 80 U.S. and foreign patents, including the primary

22

reference -- this is one of their earlier patents, and I'm quite familiar with it.

23

Their system uses non-ionizing radiation to provide real-time, continuous

24

tracking of an electromagnetic transponder that's implanted in soft tissue,

25

and it's used during radiation therapy.

1           And the importance of that is that there's kind of six components to  
2 the system. There is a wireless transponder that's implanted. There is the  
3 array, which actually includes the source coils and the sensor coils, and that's  
4 where the invention lies, is in the array. There is a console that the array is  
5 attached to, which has a user interface, infrared cameras to locate the array,  
6 and then -- tracking station, which is outside of the vault.

7           And the importance of using it during radiation therapy is that the  
8 array has to be extremely low density because the radiation beam actually  
9 transmits through the array. So it's got an -- equivalent to about 3  
10 millimeters of water. So that allows the array to be left in place. No one  
11 has to go into the radiation vault during radiation therapy to move anything.

12           So getting into the case, then, the -- I'll just start by saying that a  
13 prima facie case of obviousness hasn't been established because all of the  
14 elements are not found in the prior art. The primary reference is Mate, as I  
15 noted, and that's an earlier Calypso case. Mate was directed toward  
16 localizing and tracking the marker. So Mate is attempting to differentiate  
17 between the excitation signal and the response signal from the marker. And  
18 you've got to differentiate those two signals in order to hear the response  
19 signal from the marker, which is much smaller than the excitation signal  
20 that's fed out.

21           Mate doesn't really contemplate there being this external interference  
22 from the radiation beam itself, and, in fact, there is a section of Mate that  
23 says, "The system allows the target's actual position relative to the machine  
24 isocenter to be monitored during radiation therapy so as to minimize  
25 collateral damage." It just kind of walks right over the fact that the radiation

1 beam, when it comes on, it's such a corruptive signal. It just doesn't address  
2 it. Mate is silent with respect to that. Later, as they implemented the system  
3 for localizing and tracking, they realized that they needed to deal with the  
4 radiation beam.

5 And so this case is dealing with the radiation beam. And so different  
6 than -- both problems exist. The problem that Mate is doing, which is  
7 differentiating between the excitation signal and the marker signal, that still  
8 must be done to locate the marker. But now we're dealing with a second  
9 problem, which is dealing with the corruptive therapeutic radiation source.  
10 And so there is differentiating, which Mate is doing. There is filtering,  
11 which Acker is doing. Acker uses the conventional electronic signal filter,  
12 and when the signal comes through, any type of signal filter, the idea is to  
13 identify the characteristics of the signal in order to clean it up and allow the  
14 signal to pass more cleanly through.

15 So most conventional filters are directed toward matching that signal.  
16 In this case, this case is directed toward matching the corruption. It's trying  
17 to identify when does the corruption come through. And then when they  
18 detect corruption, all of the data is thrown out. So instead of -- it's  
19 discarding, which is the Claim 1 -- instead of either differentiating or  
20 filtering. We're not allowing the filter to go through. And so it's a little  
21 counter-intuitive from what's being taught.

22 What's being taught in Mate is to differentiate, which would make  
23 sense -- if you've got some type of corruptive, you know, interference, you'd  
24 want to differentiate it. That makes sense -- or filtering. You would identify  
25 the signal that you'd want to go through, and you would kind of push

1 everything else out of the way. But in this case, we're actually identifying  
2 the corruptive when the radiation therapy beam is on. And we're discarding  
3 everything.

4 JUDGE LEBOVITZ: Can you point where the spec correlation  
5 processor is described?

6 MS. BETCHER: So I actually looked up that term, and the term isn't  
7 in the spec. It instead is probably -- and I can find it if you'll just give me a  
8 minute, because I looked that up myself. And what it's doing is correlating  
9 those four source coils that excite the markers, and there's 32 sensor coils  
10 that listen for the response signal. And it's correlating those 32 response  
11 signals. And so it's -- that's the meaning of the correlation processor. And I  
12 can either find it right now or I can -- if you want to give me just a minute.  
13 But I did look that exact thing up.

14 JUDGE LEBOVITZ: If it's readily available to you.

15 MS. BETCHER: Yeah. Let me just -- I marked it, but I marked quite  
16 a few things. Sorry. So it -- one area that I've marked it is -- and I have the  
17 application as filed, so it's actually under description of suitable systems  
18 right at the beginning of the detailed description. And it's, oh, four  
19 paragraphs in. It describes the signal processing subsystem, and it filters,  
20 amplifies, corrects the signal receiving from the sensing subsystem --

21 JUDGE LEBOVITZ: Is there a page -- excuse me --

22 MS. BETCHER: I'm sorry. It's page 4 of the application as originally  
23 filed.

24 JUDGE LEBOVITZ: Okay. So we don't have a copy of the  
25 originally filed application? Usually, they put that in our file. Okay.

1 MS. BETCHER: I'm sorry. I really should have brought the --

2 JUDGE LEBOVITZ: I wonder what file we have -- oh, do you mean  
3 the priority document?

4 MS. BETCHER: No. This is the application as filed, page 4.

5 JUDGE SCHEINER: It is page 4. It's at the bottom of page 4 --

6 JUDGE LEBOVITZ: Okay. That would be the --

7 JUDGE SCHEINER: -- of what we have in our --

8 JUDGE LEBOVITZ: Oh.

9 MS. BETCHER: Yeah. So it's correlating the signals received from  
10 the sensing subsystem, and so --

11 JUDGE SCHEINER: I see it.

12 JUDGE LEBOVITZ: Page 4.

13 MS. BETCHER: That's --

14 JUDGE PRATS: Maybe five lines from the bottom?

15 JUDGE SCHEINER: Yeah.

16 JUDGE PRATS: The signal processing subsystem 208 filters,  
17 amplifies and correlates the signals received from the sensing subsystem. Is  
18 that what we're talking about?

19 JUDGE SCHEINER: I think so.

20 MS. BETCHER: Yes.

21 JUDGE LEBOVITZ: Oh, amplifies and correlates. Okay. Thank  
22 you.

23 MS. BETCHER: Yes. And if you have any questions on that piece --  
24 the other issue that I see is the Examiner stated in his Answer that the system  
25 and method disclosed by Mate is therapeutic. And what the Examiner is

1 addressing is the idea that even the claim -- the therapeutic radiation source.  
2 And in fact, the system and method disclosed in Mate is not therapeutic in  
3 and of itself. It's just a localization and tracking system, and it's not  
4 generating or applying any therapy whatsoever. The fact that it's not  
5 ionizing is actually the focus of the whole system. It's pretty revolutionary  
6 in the industry. And so that statement is incorrect -- the excitation source is  
7 not a therapeutic radiation source. And I think it's accepted by those skilled  
8 in the art, and it's defined in the specification that, you know, a therapeutic  
9 radiation source refers to medical use of ionizing radiation to treat cancer.  
10 So those two things should -- changed.

11 JUDGE SCHEINER: Do you have any further questions?

12 JUDGE LEBOVITZ: So the idea -- so the prior art did not teach that  
13 the magnetic flux from the marker would be corrupted by the radiation?

14 MS. BETCHER: It just didn't think about it. Just --

15 JUDGE LEBOVITZ: Right.

16 MS. BETCHER: Mate's silent with respect to that. And again, the  
17 difference, I think, is that it's discarding that data. I mean, in view of the art  
18 that we have, differentiating between two signals or filtering a signal in  
19 order to allow a signal to pass through cleaner, that's a typical electronic  
20 filter that you would expect to see, and that's what's disclosed in Acker --

21 JUDGE LEBOVITZ: Right.

22 MS. BETCHER: But this is actually just discarding the signal and  
23 the corruption because that's how they dealt with it, which is a little counter-  
24 intuitive, and it's certainly not --

25



1 JUDGE LEBOVITZ: Right. And the Examiner said, well, it would  
2 be obvious to remove noise, but the problem is there is no teaching that the  
3 radiation would cause noise in the flux?

4 MS. BETCHER: Yes, exactly.

5 JUDGE SCHEINER: That's it.

6 MS. BETCHER: Okay. Thank you.

7 JUDGE SCHEINER: I think we understand the issues, and I think  
8 that was very helpful.

9 MS. BETCHER: Oh, thank you. So all of these years, but I've never  
10 had an oral hearing. So thank you --

11 JUDGE SCHEINER: Well, good job.

12 MS. BETCHER: -- for my first opportunity.

13 JUDGE SCHEINER: You were very well-prepared.

14 JUDGE PRATS: You actually answered the question I was going to  
15 ask before I got to ask it, so --

16 JUDGE SCHEINER: Right.

17 MS. BETCHER: Well, thank you for that very much. I appreciate  
18 your time this morning.

19 COURT REPORTER: Excuse me. Before you go, can I get a  
20 business card?

21 MS. BETCHER: Absolutely.

22 COURT REPORTER: Okay.

23 MS. BETCHER: Hope you have a great day.

24

25

1 JUDGE LEBOVITZ: Thank you.

2 JUDGE SCHEINER: You, too.

3 (Whereupon, the proceedings, at 9:16 a.m., were concluded.)

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25